Sayed Sohair K, Galal Sherif H, Herdan Omar M, Mahran Ayman M
Egypt J Immunol. 2014;21(2):9-21.
Transforming growth factor β1 (TGF-β1) has a large role in the control of autoimmunity. Single nucleotide polymorphisms (SNP) in the promoter of TGF-β1 cytokine gene are known to alter the production of this important cytokine. Decreased levels of TGF-β1 may contribute to systemic lupus erythematosus (SLE) susceptibility, activity and organ damage. Lupus nephritis (LN) occurs in more than one-third of patients with SLE. In this study we measured serum levels of TGF-β1 and assessed TGF-β1 single nucloetide polymorphism (SNP) at codon 10 (T869C) in Egyptian SLE population in order to verify whether there is a relationship between this polymorphism, serum level of TGF-β1, SLE susceptibility, clinical manifestations and lupus nephritis. We studied 56 consecutive SLE female patients and 40 healthy female volunteers as control group. Serum levels of TGF-β1 were measured by enzyme-linked immunosorbent assay (ELISA) and the polymorphism of the TGF-β1 gene, T869C was analyzed using the method of amplification refractory mutation system-polymerase chain reaction (ARMS-PCR). The genotype and allele frequencies of T869C of the TGF-β1 gene did not differ between SLE patients and healthy controls. Serum levels of TGF-β1 were significantly reduced in patients with SLE as compared with levels in healthy controls (P < 0.001). The genotype and allele frequencies of T869C of the TGF-β1 gene did not differ between SLE patients with lupus nephritis (LN) and SLE patients without LN. Lower levels of TGF-β1 were found in patients with LN than in patients without LN. TGF-β1 was significantly decreased in TT group than in CC and TC groups (P < 0.001). No significant correlation was found between serum TGF-β1 level, SLEDAI scores and clinical manifestations. In conclusion, these results suggest that T869C polymorphism of the TGF-β1 gene is not associated with SLE disease susceptibility and specific clinical manifestations. However, this polymorphism may lead to the production of low serum level of TGF-β1 especially with TT genotype and consequently plays an important role in the development of renal damage.
转化生长因子β1(TGF-β1)在自身免疫控制中发挥着重要作用。已知TGF-β1细胞因子基因启动子中的单核苷酸多态性(SNP)会改变这种重要细胞因子的产生。TGF-β1水平降低可能导致系统性红斑狼疮(SLE)易感性、活动度及器官损害。超过三分之一的SLE患者会发生狼疮性肾炎(LN)。在本研究中,我们检测了埃及SLE患者群体中TGF-β1的血清水平,并评估了第10密码子(T869C)处的TGF-β1单核苷酸多态性(SNP),以验证该多态性、TGF-β1血清水平、SLE易感性、临床表现及狼疮性肾炎之间是否存在关联。我们研究了56例连续的SLE女性患者,并以40名健康女性志愿者作为对照组。采用酶联免疫吸附测定(ELISA)法检测TGF-β1的血清水平,并使用扩增阻滞突变系统-聚合酶链反应(ARMS-PCR)法分析TGF-β1基因的T869C多态性。SLE患者与健康对照组之间TGF-β1基因T869C的基因型和等位基因频率无差异。与健康对照组相比,SLE患者的TGF-β1血清水平显著降低(P < 0.001)。狼疮性肾炎(LN)的SLE患者与无LN的SLE患者之间TGF-β1基因T869C的基因型和等位基因频率无差异。LN患者的TGF-β1水平低于无LN的患者。TT组的TGF-β1水平显著低于CC组和TC组(P < 0.001)。血清TGF-β1水平、SLE疾病活动指数(SLEDAI)评分与临床表现之间未发现显著相关性。总之,这些结果表明,TGF-β1基因的T869C多态性与SLE疾病易感性及特定临床表现无关。然而,这种多态性可能导致血清TGF-β1水平降低,尤其是TT基因型,从而在肾脏损害的发生中起重要作用。